drugset

drugset / Trial / NCT01069133

Study of Rifaximin in Minimal Hepatic Encephalopathy

NCT01069133 ↗

Phase 1/2 Completed 20 enrolled Hunter Holmes Mcguire Veteran Affairs Medical Center Bausch Health Americas, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Rifaximin therapy will improve brain functioning on MRI scanning and change the microbiome and metabolome.

Timeline

Start: 2010-02
Primary completion: 2012-05
Completion: 2012-12

Publications

Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, Fuchs M, Ridlon JM, Daita K, Monteith P, Noble NA, White MB, Fisher A, Sikaroodi M, Rangwala H, Gillevet PM. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013;8(4):e60042. doi: 10.1371/journal.pone.0060042. Epub 2013 Apr 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rifaximin	Other / unclassified	550 mg	Oral

Indications